NFL Biosciences : Mise à disposition du Rapport Financier Semestriel au 30 juin 2021
04 oct. 2021 02h15 HE
|
NFL BIOSCIENCES
NFL Biosciences : Mise à disposition du Rapport Financier Semestriel au 30 juin 2021 NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), société biopharmaceutique développant des...
NFL Biosciences: Availability of the Half Year Financial Report as of June 30, 2021
04 oct. 2021 02h15 HE
|
NFL BIOSCIENCES
NFL Biosciences: Availability of the Half Year Financial Report as of June 30, 2021 NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALNFL a biopharmaceutical company developing botanical...
NFL BIOSCIENCES : Activités et résultats du 1er semestre 2021
04 oct. 2021 02h00 HE
|
NFL BIOSCIENCES
NFL Biosciences : Activités et résultats du 1er semestre 2021 Admission sur Euronext Growth Paris : 5 M€ levés auprès d’investisseurs institutionnels, historiques et individuels (juillet 2021) ...
NFL BIOSCIENCES: 2021 half-year financial and business report
04 oct. 2021 02h00 HE
|
NFL BIOSCIENCES
NFL Biosciences: 2021 half-year financial and business report Admission on Euronext Growth Paris: €5m raised from institutional, historical, and individual investors (July 2021) CESTO II Phase...
NFL BIOSCIENCES : Accord de délivrance de son brevet aux États-Unis
21 sept. 2021 12h15 HE
|
NFL BIOSCIENCES
NFL BIOSCIENCES : Accord de délivrance de son brevet aux États-Unis NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), société biopharmaceutique développant des médicaments botaniques...
NFL BIOSCIENCES: approval for its patent to be granted in the United States
21 sept. 2021 12h15 HE
|
NFL BIOSCIENCES
NFL BIOSCIENCES: approval for its patent to be granted in the United States NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs...
NFL Biosciences : l’étude clinique de Phase II/III de NFL-101 pour le sevrage tabagique approuvée en France
15 sept. 2021 12h00 HE
|
NFL BIOSCIENCES
NFL Biosciences : l’étude clinique de Phase II/III de NFL-101 pour le sevrage tabagique approuvée en France L’étude clinique de Phase II/III, intitulée CESTO II, a été approuvée par l’ANSM et a reçu...
NFL BIOSCIENCES: Phase II/III clinical trial for NFL-101 for smoking cessation approved in Franc
15 sept. 2021 12h00 HE
|
NFL BIOSCIENCES
NFL Biosciences: Phase II/III clinical trial for NFL-101 for smoking cessation approved in France The CESTO II Phase II/III clinical trial has been approved by the French National Agency for the...
NFL BIOSCIENCES : INITIATION DE COUVERTURE ANALYSTE PAR INVEST SECURITIES
06 sept. 2021 02h45 HE
|
NFL BIOSCIENCES
NFL BIOSCIENCES : INITIATION DE COUVERTURE ANALYSTE PAR INVEST SECURITIES Recommandation : ACHATObjectif de cours : 4,90 € NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), société...
NFL BIOSCIENCES: ANALYST COVERAGE LAUNCHED WITH INVEST SECURITIES
06 sept. 2021 02h45 HE
|
NFL BIOSCIENCES
NFL BIOSCIENCES: ANALYST COVERAGE LAUNCHED WITH INVEST SECURITIES Recommendation: BUYTarget share price: €4.90 NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical...